Breathe Well Live Well
Condition: Asthma
Interventions: Drug: CHF 5993 100/6/12.5 µg; Drug: CHF 1535 100/6 µg
Sponsor: Chiesi Farmaceutici S.p.A.
Not yet recruiting – verified February 2016
View full post on ClinicalTrials.gov: asthma | received in the last 14 days
Regulatory Focus |
Researchers Link FDA Actions to Decrease in LABA Use in Asthma Treatment
Regulatory Focus A recent study finds an association between regulatory actions by the US Food and Drug Administration (FDA) and the use of long-acting ?2-agonists (LABA) commonly used to treat asthma. The study, published in the Journal of Allergy and Clinical … Simple asthma screening test could improve care for children |
View full post on asthma – Google News
MedPage Today |
Asthma: LABA + Steroids Not a Winning Combo for Blacks
MedPage Today Asthma exacerbations were not reduced in black adults when a long acting beta-agonist (LABA) was added to treatment with inhaled corticosteroids (ICS), a randomized trial concluded. The mean number of exacerbations was 0.42 exacerbations per … Study compares combination treatments for black adults with asthma The JAMA … |
View full post on asthma – Google News
Monthly Prescribing Reference (registration) |
LAMA LABA Uncontrolled Asthma ICS
Monthly Prescribing Reference (registration) Long-acting muscarinic antagonists (LAMA) have been shown to reduce exacerbations of chronic obstructive pulmonary disease (COPD) and are now being considered for patients with uncontrolled asthma as add-on treatment. A review in the Cochrane … |
View full post on asthma – Google News
|
Once Asthma is Under Control, Should LABA Tx Be Stopped?
Monthly Prescribing Reference (registration) Long-acting beta2-agonists (LABA) are often prescribed to adults with asthma not well controlled by inhaled corticosteroid (ICS) treatment but may carry an increased risk of serious adverse events and mortality. An article in the Cochrane Library … |
View full post on asthma – Google News
Condition: Asthma
Interventions: Drug: Fluticasone Furoate; Drug: Vilanterol; Drug: Fluticasone propionate; Drug: Salmeterol; Drug: Budesonide; Drug: Formoterol Fumarate
Sponsor: GlaxoSmithKline
Not yet recruiting – verified May 2015
View full post on ClinicalTrials.gov: asthma | received in the last 14 days
Science World Report |
Blame LABA Risks in Asthma on Gene Variants?
MedPage Today Six variants in the beta2-adrenergic receptor gene (ADRB2) found in fewer than 5% of LABA-treated asthma patients were associated with double the incidence of a related hospital admission overall compared with common variants (44% versus 22% in 12 … LABA Drugs for Asthma May Negatively Impact People With Rare Genetic … Rare Genetic Variations May Account For Severe Reaction To LABA Drugs In … |
View full post on asthma – Google News
|
Doubt cast on LABA withdrawal in combination asthma therapy
News-Medical.net By Caroline Price, Senior medwireNews Reporter. Researchers have urged doctors to be cautious over withdrawal of long-acting beta-2 agonist (LABA) therapy in patients with asthma controlled by this type of bronchodilator in combination with an inhaled … |
View full post on asthma – Google News
|
LABA Withdrawal Increases Asthma-Related Impairment
Journal of the American Academy of Physician Assistants (HealthDay News) – For patients with asthma controlled with a combination of an inhaled corticosteroid (ICS) and a long-acting ?2-agonist (LABA), withdrawal of the LABA once asthma is controlled correlates with increased asthma-associated impairment. |
View full post on asthma – Google News
|
Combination of ICS and LABA appears to reduce severe asthma attacks
News-Medical.net A Henry Ford Hospital study has found that using two types of common asthma medications in combination reduces severe asthma attacks. Researchers say using long-acting beta-agonists (LABAs) in fixed-dose combination with inhaled corticosteroid (ICS) … |
View full post on asthma – Google News